Oxford Biomedica expands Agreement with Juno Therapeutics, a Bristol Myers Squibb company; adding two new viral vector programmes for Bristol Myers Squibb CAR-T therapies
The information contained within this announcement is deemed by the Group to constitute inside information as stipulated under the Market Abuse Regulation (EU) No. 596/2014 (as it forms part of…